New mRNA bird flu vaccine shows promise in early trials

NCT ID NCT06382311

Completed ⭐️ VACCINE ⭐️ Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new mRNA vaccine designed to protect against a potential pandemic of H5 bird flu. Nearly 1,000 healthy adults aged 18 to 85 received different doses to find the safest and most effective one. Researchers monitored side effects like pain, fever, and fatigue, and measured the immune response through blood tests. The goal is to have a ready vaccine if a bird flu outbreak ever becomes a global threat.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

avian influenza influenza prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INFLUENZA, HUMAN

Contacts and locations

Locations

GSK Investigational Site

Anniston, Alabama, 36207, United States
GSK Investigational Site

Little Rock, Arkansas, 72204, United States
GSK Investigational Site

Fort Collins, Colorado, 80525, United States
GSK Investigational Site

Fort Myers, Florida, 33912, United States
GSK Investigational Site

West Palm Beach, Florida, 33409, United States
GSK Investigational Site

Chamblee, Georgia, 30043, United States
GSK Investigational Site

El Dorado, Kansas, 67042, United States
GSK Investigational Site

Lenexa, Kansas, 66219, United States
GSK Investigational Site

Lexington, Kentucky, 40509, United States
GSK Investigational Site

Kansas City, Missouri, 64114, United States
GSK Investigational Site

Omaha, Nebraska, 68144, United States
GSK Investigational Site

Las Vegas, Nevada, 89102, United States
GSK Investigational Site

Rochester, New York, 14609, United States
GSK Investigational Site

Greensboro, North Carolina, 27405, United States
GSK Investigational Site

Winston-Salem, North Carolina, 27103, United States
GSK Investigational Site

Edmond, Oklahoma, 73013, United States
GSK Investigational Site

Yukon, Oklahoma, 73099, United States
GSK Investigational Site

Philadelphia, Pennsylvania, 19111, United States
GSK Investigational Site

Austin, Texas, 78705, United States
GSK Investigational Site

Norfolk, Virginia, 23502, United States
GSK Investigational Site

Seattle, Washington, 98104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.